Ovarian Epithelioid Hemangioendothelioma. Case Report

Authors

  • V. SVINTSITSKIY State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • N. TSIP State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • S. NESPRYADKO State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • O. SAMOKHVALOVA State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • O. KHOPTIANA State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • D. YERIUSHKIN State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • M. KROTEVYCH State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • S. TROKHYMYCH State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine
  • L. SKORODA State Non-Commercial Enterprise «National Cancer Institute», Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.04.402

Keywords:

epithelioid hemangioendothelioma, ovary tumor, treatment

Abstract

Epithelioid hemangioendothelioma is a rare vascular sarcoma commonly occurring in the liver, soft tissues, and organs of the chest cavity. This study provides a detailed description of the clinical presentation, diagnosis, and treatment of epithelioid hemangioendothelioma of the ovary in a 71-year-old patient. According to the pathohistological examination, a mesenchymal tumor of the ovary with epithelioid cells was diagnosed. The immunohistochemical tests confirmed the diagnosis of epithelioid hemangioendothelioma. This clinical case is of interest for clinical practitioners due to the rare location of the tumor in female reproductive organs, which has not been previously documented in the medical literature.

References

Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Can- cer. 1982;50(5):970-981. https://doi.org/10.1002/1097-0142(19820901)50:5<970::aid-cncr2820500527>3.0.co; 2-z

Wang ZB, Yuan J, Chen W, Wei LX. Transcription factor ERG is a specific and sensitive diagnostic marker for hepatic angiosarcoma. World J Gastroenterol. 2014;20(13):3672-3679. https://doi.org/10.3748/wjg.v20.i13.3672

Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or with- out pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140(5):1312- 1318. https://doi.org/10.1378/chest.11-0039

Stacchiotti S, Frezza AM, Blay JY, et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934-2942. https://doi.org/10.1002/cncr.33618

de Pinieux G, Karanian M, Le Loarer F, et al. Nationwide incidence of sarcomas and connective tissue tumors of in- termediate malignancy over four years using an expert pathology review network. PLoS ONE. 2021;16(2):e0246958. https://doi.org/10.1371/journal.pone.0246958

Nagtegaal ID, Odze RD, Klimstra D, et al. WHO Classification of Tumours Editorial Board. The 2019 WHO clas- sification of tumours of the digestive system. Histopathology. 2020;76:182-188. https://doi.org/10.1111/his.13975

Tomassen T, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, et al. Prognostic factors in epithelioid hemangio- endothelioma: Analysis of a nationwide molecularly/immunohistochemically confirmed cohort of 57 cases. Cancers (Basel). 2023;15(13):3304. https://doi.org/10.3390/cancers15133304

Stacchiotti S, Miah AB, Frezza AM, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open. 2021;6(3):100170. https://doi.org/10.1016/j.esmoop.2021.100170.

Radzikowska E, Szczepulska-Wójcik E, Chabowski M, et al. Pulmonary epithelioid haemangioendothelioma—Inter- feron 2-alpha treatment—case report. Adv Respir Med. 2008;76(4):281-285. https://doi.org/10.5603/ARM.27887

Thomas RM, Aloia TA, Truty MJ, et al. Treatment sequencing strategy for hepatic epithelioid haemangioendothe- lioma. HPB (Oxford). 2014;16:677-685. https://doi.org/ 10.1111/hpb.12202

Esma S, Marie-Christine SP, Jean G et al. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate. Oncol Res Treat. 2014;37(3):124-126. https://doi.org/10.1159/000360208

Mayur V, Mohammed S, Radwan D, et al. Hepatic hemangioendothelioma: An update. World J Gastrointest Oncol.

;12(3):248-266. https://doi.org/10.4251/wjgo.v12.i3.248

Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257-263. https://doi.org/10.1093/ annonc/mds237

Shuang M, Ryan K, Ajaybabu V P, et al. The TAZ-CAMTA1 fusion protein promotes tumorigenesis via con- nective tissue growth factor and Ras-MAPK signaling in epithelioid hemangioendothelioma. Clin Cancer Res. 2022;28(14):3116-3126. https://doi.org/10.1158/1078-0432.CCR-22-0421

Downloads

Published

12.12.2024

How to Cite

SVINTSITSKIY, V., TSIP, N., NESPRYADKO, S., SAMOKHVALOVA, O., KHOPTIANA, O., YERIUSHKIN, D., … SKORODA, L. (2024). Ovarian Epithelioid Hemangioendothelioma. Case Report. Experimental Oncology, 46(4), 402–407. https://doi.org/10.15407/exp-oncology.2024.04.402

Most read articles by the same author(s)